- Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily Tio in improving quality of life in people with uncontrolled asthma1
- IND/GLY/MF recently received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) and is currently under regulatory review in multiple countries
- If approved, once-daily IND/GLY/MF will be the first LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with LABA/ICS treatment and could provide an effective and convenient alternative to the current standard-of-care regimen
PR Newswire
TOKYO and LONDON, June 5, 2020